| Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II Impact-II Investigators The Lancet 349 (9063), 1422-1428, 1997 | 866 | 1997 |
| Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a … JH Alexander JAMA: Journal of the American Medical Association 294 (19), 2005 | 782 | 2005 |
| Results of PREVENT III: a multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery MS Conte, DF Bandyk, AW Clowes, GL Moneta, L Seely, TJ Lorenz, ... Journal of vascular surgery 43 (4), 742-751. e1, 2006 | 695 | 2006 |
| Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial Esprit Investigators Lancet (London, England) 356 (9247), 2037-2044, 2000 | 608 | 2000 |
| Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: the ESPRIT trial: a randomized controlled trial JC O'Shea, GE Hafley, S Greenberg, V Hasselblad, TJ Lorenz, MM Kitt, ... Jama 285 (19), 2468-2473, 2001 | 301 | 2001 |
| Rationale and design of the acute study of clinical effectiveness of nesiritide in decompensated heart failure trial (ASCEND-HF) AF Hernandez, CM O'Connor, RC Starling, CJ Reist, PW Armstrong, ... American heart journal 157 (2), 271-277, 2009 | 179 | 2009 |
| Relation of early saphenous vein graft failure to outcomes following coronary artery bypass surgery AR Halabi, JH Alexander, LK Shaw, TJ Lorenz, L Liao, DF Kong, ... The American journal of cardiology 96 (9), 1254-1259, 2005 | 164 | 2005 |
| Inhibition of endotoxin-induced cytokine release and neutrophil activation in humans by use of recombinant bactericidal/permeability-increasing protein MAM von der Möhlen, AN Kimmings, NI Wedel, MLCM Mevissen, ... Journal of Infectious Diseases 172 (1), 144-151, 1995 | 151 | 1995 |
| Early percutaneous coronary intervention, platelet inhibition with eptifibatide, and clinical outcomes in patients with acute coronary syndromes NS Kleiman, AM Lincoff, GC Flaker, KS Pieper, RG Wilcox, LG Berdan, ... Circulation 101 (7), 751-757, 2000 | 149 | 2000 |
| Pharmacodynamics and pharmacokinetics of higher-dose, double-bolus eptifibatide in percutaneous coronary intervention IC Gilchrist, JC O’Shea, T Kosoglou, LK Jennings, TJ Lorenz, MM Kitt, ... Circulation 104 (4), 406-411, 2001 | 112 | 2001 |
| Immediate coronary artery bypass surgery after platelet inhibition with eptifibatide: results from PURSUIT CM Dyke, D Bhatia, TJ Lorenz, SP Marso, BE Tardiff, C Hogeboom, ... The Annals of thoracic surgery 70 (3), 866-871, 2000 | 112 | 2000 |
| The design and rationale for the acute medically ill venous thromboembolism prevention with extended duration betrixaban (APEX) study AT Cohen, R Harrington, SZ Goldhaber, R Hull, CM Gibson, ... American heart journal 167 (3), 335-341, 2014 | 101 | 2014 |
| Effects of administration of an anti‐cd5 plus immunoconjugate in rheumatoid arthritis. results of two phase ii studies V Strand, PE Lipsky, GW Cannon, LH Calabrese, C Wiesenhutter, ... Arthritis & Rheumatism: Official Journal of the American College of …, 1993 | 97 | 1993 |
| A phase 2 randomized, double-blind, placebo-controlled trial of PRT064445, a novel, universal antidote for direct and indirect factor Xa inhibitors M Crowther, M Kitt, T Lorenz, V Mathur, G Lu, A Hutchaleelaha, ... J Thromb Haemost 11 (suppl 2), 30, 2013 | 92 | 2013 |
| Clinical pharmacology of higher dose eptifibatide in percutaneous coronary intervention (the PRIDE study) JE Tcheng, JD Talley, JC O’Shea, IC Gilchrist, NS Kleiman, CL Grines, ... The American journal of cardiology 88 (10), 1097-1102, 2001 | 87 | 2001 |
| A double‐blind, placebo‐controlled study of anti‐CD5 immunoconjugate in patients with rheumatoid arthritis NJ Olsen, RH Brooks, JJ Cush, PE Lipsky, EW St. Clair, EL Matteson, ... Arthritis & Rheumatism: Official Journal of the American College of …, 1996 | 68 | 1996 |
| Relationship of creatine kinase-myocardial band release to Thrombolysis in Myocardial Infarction perfusion grade after intracoronary stent placement: an ESPRIT substudy CM Gibson, SA Murphy, SJ Marble, DJ Cohen, EA Cohen, HK Lui, ... American Heart Journal 143 (1), 106-110, 2002 | 64 | 2002 |
| The PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) trial: study rationale, design, and baseline patient characteristics JH Alexander, TB Ferguson Jr, DM Joseph, MJ Mack, RK Wolf, ... American heart journal 150 (4), 643-649, 2005 | 63 | 2005 |
| Is glycoprotein IIb/IIIa antagonism as effective in women as in men following percutaneous coronary intervention? Lessons from the ESPRIT study LS Fernandes, JE Tcheng, JC O’Shea, B Weiner, TJ Lorenz, C Pacchiana, ... Journal of the American College of Cardiology 40 (6), 1085-1091, 2002 | 62 | 2002 |
| Design and rationale of the PREVENT III clinical trial: edifoligide for the prevention of infrainguinal vein graft failure MS Conte, TJ Lorenz, DF Bandyk, AW Clowes, GL Moneta, BL Seely Vascular and endovascular surgery 39 (1), 15-23, 2005 | 61 | 2005 |
